Can Pfizer Bank on New Immunotherapy Bavencio for Growth? – Nasdaq
|
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Nasdaq As demand for immuno-oncology drugs and their combinations rises, Pfizer, Inc. ‘s PFE newly approved immunotherapy, Bavencio, is being considered a significant top-line driver for this New York-based pharma giant. Pfizer’s shares are up 5.8% so far … |
Medical Xpress |
Scientists develop novel immunotherapy technology for prostate cancer
Medical Xpress “This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,” said David B. Weiner, Ph.D., executive vice president of The Wistar … |
|
BioMarin to Include Additional Phase 3 Trial for Hemophilia A Gene Therapy
Specialty Pharmacy Times An additional phase 3 study investigating the novel gene therapy BMN 270 for the treatment of hemophilia A will be added as part of BioMarin Pharmaceutical’s development plan for the drug. Two separate studies will be conducted to examine the safety … |
Express.co.uk |
Blood cancer: High doses of vitamin C could encourage stem cells to die
Express.co.uk Researchers say Vitamin C may “tell” faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. They explained that certain genetic changes are known to reduce the ability of an enzyme called TET2 to … |
|
Wistar scientists develop novel immunotherapy technology for prostate cancer
EurekAlert (press release) “This is an important demonstration of the possibilities opened up for immunotherapy by DMAb technology to direct in vivo production of antibodies of major relevance to human cancer,” said David B. Weiner, Ph.D., executive vice president of The Wistar … |